Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis

Figures & data

Figure 1 Distribution of injections of vascular-targeting agents performed per year.

Figure 2 Indications for intravitreal injection based on primary diagnosis.

Table 1 Baseline characteristics of patients treated with vascular-targeting agents

Demographic	Bevacizumab	Ranibizumab	Triamcinolone
	Group (n = 7315)	Group (n = 981)	Group (n = 1846)
Age (years)
Median	67.8	79.5	67.3
Range	12.3–88.0	21.3–87.1	15.8–87.7
Gender
Female	55.3%	54.2%	50.5%
Male	44.7%	45.8%	49.5%
Race
Hispanic	24.9%	27.9%	22%
Non-Hispanic White	65.8%	68.1%	64.4%
Native American	0.4%	–	–
African American	6.6%	0.9%	10.2%
Asian	1.0%	0.2%	3.4%
Other	1.3%	2.9%	–

Figure 3 Photograph showing anterior segment of the right eye three days after intravitreal injection with bevacizumab, visual acuity was 5/200. Photo to the right demonstrates conjunctival redness and swelling. Photo to the left displaying hypopyon and scleral redness.

Figure 4 B-scan echography of the right eye showing vitreous opacities with membranes, typical of endophthalmitis.